HSK42360
Phase 1Small molecule
Haisco Pharmaceutical Group Co., Ltd.HSK42360 is one of 4 small molecule programs targeting BRAF V600 Mutation. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in BRAF V600 Mutation
#DrugCompanyPhaseTrials
1Tafinlar
NovartisPhase 2
Mekinist
NovartisPhase 2
HSK42360
Haisco Pharmaceutical Group Co., Ltd.Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HSK42360. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details